» Articles » PMID: 37446114

S-Nitrosylation of Tissue Transglutaminase in Modulating Glycolysis, Oxidative Stress, and Inflammatory Responses in Normal and Indoxyl-Sulfate-Induced Endothelial Cells

Overview
Journal Int J Mol Sci
Publisher MDPI
Date 2023 Jul 14
PMID 37446114
Authors
Affiliations
Soon will be listed here.
Abstract

Circulating uremic toxin indoxyl sulfate (IS), endothelial cell (EC) dysfunction, and decreased nitric oxide (NO) bioavailability are found in chronic kidney disease patients. NO nitrosylates/denitrosylates a specific protein's cysteine residue(s), forming S-nitrosothios (SNOs), and the decreased NO bioavailability could interfere with NO-mediated signaling events. We were interested in investigating the underlying mechanism(s) of the reduced NO and how it would regulate the S-nitrosylation of tissue transglutaminase (TG2) and its substrates on glycolytic, redox and inflammatory responses in normal and IS-induced EC injury. TG2, a therapeutic target for fibrosis, has a Ca-dependent transamidase (TGase) that is modulated by S-nitrosylation. We found IS increased oxidative stress, reduced NADPH and GSH levels, and uncoupled eNOS to generate NO. Immunoblot analysis demonstrated the upregulation of an angiotensin-converting enzyme (ACE) and significant downregulation of the beneficial ACE2 isoform that could contribute to oxidative stress in IS-induced injury. An in situ TGase assay demonstrated IS-activated TG2/TGase aminylated eNOS, NFkB, IkBα, PKM2, G6PD, GAPDH, and fibronectin (FN), leading to caspases activation. Except for FN, TGase substrates were all differentially S-nitrosylated either with or without IS but were denitrosylated in the presence of a specific, irreversible TG2/TGase inhibitor ZDON, suggesting ZDON-bound TG2 was not effectively transnitrosylating to TG2/TGase substrates. The data suggest novel roles of TG2 in the aminylation of its substrates and could also potentially function as a Cys-to-Cys S-nitrosylase to exert NO's bioactivity to its substrates and modulate glycolysis, redox, and inflammation in normal and IS-induced EC injury.

Citing Articles

Targeting pyruvate kinase M2 for the treatment of kidney disease.

Chen D, Han J, Liu H, Feng K, Li P Front Pharmacol. 2024; 15:1376252.

PMID: 38910890 PMC: 11190346. DOI: 10.3389/fphar.2024.1376252.

References
1.
Reynaert N, Ckless K, Korn S, Vos N, Guala A, Wouters E . Nitric oxide represses inhibitory kappaB kinase through S-nitrosylation. Proc Natl Acad Sci U S A. 2004; 101(24):8945-50. PMC: 428452. DOI: 10.1073/pnas.0400588101. View

2.
Hilfiker A, Hilfiker-Kleiner D, Fuchs M, Kaminski K, Lichtenberg A, Rothkotter H . Expression of CYR61, an angiogenic immediate early gene, in arteriosclerosis and its regulation by angiotensin II. Circulation. 2002; 106(2):254-60. DOI: 10.1161/01.cir.0000021426.87274.62. View

3.
Slaughter T, Achyuthan K, Lai T, Greenberg C . A microtiter plate transglutaminase assay utilizing 5-(biotinamido)pentylamine as substrate. Anal Biochem. 1992; 205(1):166-71. DOI: 10.1016/0003-2697(92)90594-w. View

4.
Staffler R, Pasternack R, Hils M, Kaiser W, Moller F . Nucleotide binding kinetics and conformational change analysis of tissue transglutaminase with switchSENSE. Anal Biochem. 2020; 605:113719. DOI: 10.1016/j.ab.2020.113719. View

5.
Sun J, Steenbergen C, Murphy E . S-nitrosylation: NO-related redox signaling to protect against oxidative stress. Antioxid Redox Signal. 2006; 8(9-10):1693-705. PMC: 2443861. DOI: 10.1089/ars.2006.8.1693. View